Early Detection of Advanced Fatty Liver Disease

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the western world, affecting one in every three subjects.

The investigators hypothesize that a patient population without known liver disease has a certain percentage of patients with liver fibrosis who are undiagnosed and not monitored.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-Alcoholic Fatty Liver Disease Digestive System Diseases Fatty Liver Fibrosis Liver Cirrhosis Liver Diseases Liver Fibrosis Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

45 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Haemek medical center

Afula, 1834111, Israel

About this study

The investigators will run an algorithm for the non-invasive diagnosis of advanced fibrosis in non-alcoholic fatty liver disease on a participants without known liver disease.

Nafld Score and Elastography are now being used to predict the severity of liver fibrosis and deciding whether the patient is going to a biopsy, clinical follow-up or further investigation of liver cirrhosis and complications.

The detection of participants with Nafld Score more than 0.675 (advanced fibrosis) will enroll them to an elastography test. Participants with advanced fibrosis according to elastography will be introduced to follow-up and treatment that should delay or prevent progression of the disease to more advanced conditions like: cirrhosis, portal hypertension, esophageal varicose veins and hepatocellular carcinoma.

If the investigators find that the results of the study are consistent with their hypothesis, this will lead to applying the flowchart to a larger sample of population in order to use it as a future survey.

Moreover, the investigators will check whether there is a correlation between Nafld Score and elastography in participants without know liver disease with Nafld Score more than 0.675.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects aged 45-60 who belong to an initial clinic which was chosen arbitrarily.
Subjects without known liver disease.
Subjects agree to sign a consent form. -

Exclusion criteria

History of right-sided heart failure
History of liver disease including positive infectious serology for hepatitis B or C
Pregnant women
People incapable of judgment -

Treatment and study plan

Primary outcomes

Non-Alcoholic Fatty Liver Disease Score

Time frame: Up to five minutes

Non-alcoholic fatty liver disease Score (Nafld Score) is a non-invasive scoring system based on several laboratory tests that helps to estimate the amount of scarring in the liver. The score is made up of six parameters: age, BMI(body mass index), aspartate aminotransferase(AST) / alanine transaminase(ALT), platelet count, impaired fasting glucose(IFG), albumin.

The Nafld Score formula is: -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelets (×10^9/l) - 0.66 × albumin (g/dl).

2 cutoff points were selected to identify the presence (> 0.675) and absence (< -1.455) of significant fibrosis.

< -1.455: predictor of absence of significant fibrosis (F0-F2 fibrosis), negative predictive value 93% .

between -1.455 and 0.675: indeterminate score.

>0.675: predictor of presence of significant fibrosis (F3-F4 fibrosis), positive predictive value of 90%.

The score will be calculated for all the participants.

Secondary outcomes

Elastography Test

Time frame: Up to two hours

Ultrasound Elastography is a non-invasive test which uses the technology of Shear Wave Elastography (SWE) obtained from the right liver lobe for staging liver fibrosis according to Metavir Fibrosis Score with sensitivity between 86% -98% and specificity between 90% -93%.

Metavir Fibrosis Score is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy.

Liver fibrosis assessed by Shear Wave Elastography is well correlated to biopsy using Metavir Score.

Participants with Nafld Score above 0.675 will undergo ShearWave Elastography.

The outcome of the test will be correlated to Metavir Score system according to the chart below:

SWE (kiloPascal) , METAVIR score, Fibrosis Level.

Below 5 , F0 , No fibrosis.

5.0-7.1 , F1 , Mild Fibrosis.

7.1-8.7 , F2 , Significant Fibrosis.

8.7-10.4 , F3 , Sever Fibrosis.

10.4-19 , F4 , Cirrhosis.

Sponsors and collaborators

Lead sponsor

HaEmek Medical Center, Israel

Other

Registry information

Official study title

Prospective Study: Early Detection of Advanced Fatty Liver Disease in the General Adult Population by Using Non-Alcoholic Fatty Liver Disease Score and Elastography

Important dates

Study start: 2018
Primary completion: 2022
Study completion: 2023
First posted: Aug 1, 2018
Registry last updated: Feb 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed